Hemispherx BioPharma, Inc (HEB) Sees Significant Growth in Short Interest

Hemispherx BioPharma, Inc (NYSE:HEB) was the target of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 286,805 shares, a growth of 68.7% from the August 31st total of 170,008 shares. Currently, 1.4% of the company’s stock are short sold. Based on an average daily trading volume, of 168,879 shares, the days-to-cover ratio is presently 1.7 days.

Hemispherx BioPharma (NYSE:HEB) opened at 1.26 on Friday. Hemispherx BioPharma has a 52 week low of $0.72 and a 52 week high of $2.64. The stock has a 50 day moving average price of $1.57 and a 200 day moving average price of $1.56. The stock’s market cap is $26.14 million.

Hemispherx BioPharma (NYSE:HEB) last issued its quarterly earnings data on Monday, August 15th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. During the same quarter last year, the firm posted ($0.02) earnings per share.

About Hemispherx BioPharma

Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.

5 Day Chart for NYSE:HEB

Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.